



บริษัท เอ็กซ์ไบโอไซเอนซ์ จำกัด (มหาชน)  
304 อาคารวานิชเพลซ อารีบี (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 www.xbio.co.th

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 www.xbio.co.th

XBIO-AD011/2026

9 February 2026

Subject Notice of Rights to Subscribe for New Ordinary Shares of X Bioscience Public Company Limited

To Shareholders of X Bioscience Public Company Limited

Enclosures

1. Certificate of Rights to Subscribe for New Ordinary Shares Issued by Thailand Securities Depository Co., Ltd.
2. Notice of the Allotment and Subscription Documents of New Ordinary Shares of X Bioscience Public Company Limited
3. Subscription Form for New Ordinary Shares of X Bioscience Public Company Limited
4. Power Of Attorney for the Subscription of New Ordinary Shares of X Bioscience Public Company Limited
5. Additional Documents for Securities Subscription to be Specifically Used by Subscriber Wishing to Deposit Securities into Issuer Account
6. Map of the Location for Submission of Subscription Documents for Newly Issued Ordinary Shares
7. FATCA/CRS Self-Certification Form for Entity/Juristic Person

(Details of the enclosures are available via the QR Code below.)

The Extraordinary General Meeting of Shareholders No. 1/2026 X Bioscience Public Company Limited (**Company**), held on 3 February 2026, resolved the allocation of newly issued ordinary shares, in an amount of not exceeding 15,229,669,870 new ordinary shares, with the par value of 7.00 Baht each, shall be allotted to the existing shareholders (regardless of one or several times) by way of rights offering, at the allotment ratio of 1 existing ordinary share to 14.50 new ordinary shares. Any fraction from would be discarded. The offering price for such new ordinary shares was fixed at 0.04 Baht each.



บริษัท เอ็กซ์ไบโอไซเอนซ์ จำกัด (มหาชน)  
304 อาคารวานิชเพลส อารีวี (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 www.xbio.co.th

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 www.xbio.co.th

Due to the fact that the Company incurred accumulated losses as shown in its audited separate financial statements for 2024 ended as at 31 December 2024 and the reviewed separate financial statements ended as at 30 September 2025, the Company may determine the offering price of new ordinary shares to be lower than its par value. However, the offering price of such new ordinary shares must not be lower than 0.01 Baht per share. This is in compliance with Section 52 of Public Limited Company Act B.E. 2535 (as amended), which provides that a public company which incurs loss but has been in operation for more than 1 year may, subject to approval of shareholders meeting, offer to sell its shares with the value being lower than the par value, provided that the certain discount of share price must be fixed.

In offering of such new ordinary shares to the existing shareholders of the Company by way of rights offering, if there are new ordinary shares remaining after the completion of the allotment to the existing shareholders by way of rights offering in the first round, such remaining shares may be allotted to the existing shareholders, who wish to subscribe new ordinary in excess of their entitlement (Oversubscription) at the same offering price as the rights offering shares (the existing shareholders who exercise their oversubscription rights may be allotted the remaining shares only after the allotment of the new ordinary shares by way of rights offering has been already complete) as per the following details:

- (a) in case of the number of the remaining shares from the allotment of new ordinary shares by way of rights offering in the first round being greater or equivalent to the number of the new ordinary shares that was subscribed under the oversubscription by way of rights offering, the Company will allot the remaining shares to all existing shareholders who already subscribed under the oversubscription and fully made the subscription price according to their intention to subscribe the remaining shares under the oversubscription;
- (b) in case of the number of the remaining shares from the allotment of new ordinary shares by way of rights offering in the first round being less than the number of the new ordinary shares that was subscribed under the oversubscription by way of rights offering, the Company will allot the remaining shares to the existing shareholders who exercise their oversubscription rights as per the following procedures:
  - (1) to allot the remaining shares to the existing shareholders who exercise their oversubscription rights in proportion to their shareholdings by multiplying the shareholding of each shareholder who exercise oversubscription rights with the remaining shares, which results in the number of new ordinary shares to be allotted to



บริษัท เอ็กซ์ไบโอไซน์เซนส์ จำกัด (มหาชน)  
304 อาคารวานิชเพลส อารีบี (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 www.xbio.co.th

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 www.xbio.co.th

each of the shareholders exercising their oversubscription rights. Any fraction will be disregarded. The number of new ordinary shares to be allotted shall not exceed the number of shares subscribed and fully paid; or

- (2) in case of there being the remaining shares from the allotment under (b) (1) above, such remaining shares shall be allotted to each shareholder, who exercises the oversubscription right and has not been fully allotted the remaining shares in proportion to his/her shareholding, by multiplying the shareholding of each shareholders exercising the oversubscription right with the number of the remaining shares, which results in the number of the number of new ordinary shares to be allotted to each shareholder exercising his/her oversubscription right. Any fraction of shares resulting from the calculation will be disregarded. The number of the remaining shares to be allotted to each shareholders will not exceed the number of shares subscribed and the subscription price made. The Company will proceed with the allotment of the remaining shares to the shareholders, who exercise their oversubscription rights as per the above procedures until all remaining shares are fully allotted or no shareholder wishes to subscribe for new ordinary shares.

In case where any shareholders exercising their oversubscription rights and such oversubscription results in such shareholders their concert party and the person under Section 258 of the Securities and Exchange Act B.E. 2565 (as amended) holding shares in the Company and reaching the trigger point, which gives rise to a mandatory tender offer requirement, such shareholders shall make tender offer for all shares in the Company as required by the Notification of the Capital Market Supervisory Board No. TorJor. 12/2554 regarding criteria, conditions and procedures for Acquisition of Securities for Business Takeovers (as amended) (“**Notification TorJor. 12/2554**”), unless such shareholders are exempted from the tender offer requirement as provided in the Notification TorJor. 12/2554.

In any cases, the allotment of new ordinary shares to the existing shareholders above must not violate the foreign shareholding restrictions as specified in the Company's Articles of Association. Presently, foreigners are allowed to hold shares in the Company not more than 49 percent of the total number of issued shares of the Company.



บริษัท เอ็กซ์ไบโอไซเอนซ์ จำกัด (มหาชน)  
304 อาคารวานิชเพลซ อารีบี (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 www.xbio.co.th

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 www.xbio.co.th

In the event that there are remaining new ordinary shares after the allotment to existing shareholders by way of rights offering and under oversubscription (“**First Round Allotment**”), the Board of Directors and/or the executive committee and/or the Chief Executive Office or the designated person of the Board of Directors and/or the executive committee and/or the Chief Executive Office has discretion to wholly or partly allot such remaining new ordinary shares to the existing shareholders thereafter (regardless of one or several times (if any)) and/or propose to the shareholders’ meeting to consider and approve the reduction of registered capital by canceling all remaining new ordinary shares.

The Board of Directors’ Meeting also resolved that the record date that is used to determine the shareholders’ rights for allotment and offer of new ordinary shares and the subscription and payment period for new ordinary will be 12 January 2026 (Record Date) and the period between 23 February and 6 March 2026 (totalling 9 business days), respectively.

The Board of Directors of the Company and/or the Executive Committee and/or the Chief Executive Officer or any designated person of the Board of Directors of the Company and/or the Executive Committee and/or the Chief Executive Officer is authorized to determine the conditions, offering price, and the details of any actions relevant to the allotment of the new ordinary share, such as the division of new ordinary shares for allotting in one or several tranches, the determination of the subscription and payment period, including the change or amendment of the details in the allotment and determination of other details relating to the allotment of such new ordinary shares as deemed appropriate for the utmost benefit of the Company, which shall not be contrary or inconsistent with the law and/or rules or regulations related to the Securities and Exchange Commission, SET, and/or other relevant agencies, including but not limited to the following:

- (a) Determination or amendment of conditions and details regarding the allotment of the new ordinary shares, which includes, but not limited to, the offering, subscription and payment period, offering method, offering ratio, offering price, as well as, any conditions and details relevant to the allocation and offering of new ordinary shares;
- (b) signing the application, notice, and other instrument or relevant documents concerning the capital increase and the allotment of new ordinary shares of the Company, including the certification of relevant documents, in relating to communication and/or receiving the documents from the officer or agent of the relevant authority as well as listing the new ordinary share of the Company as listed securities on the SET or stock market, where the shares in the Company are listed at that time; and



บริษัท เอ็กซ์ไบโอไซเอนซ์ จำกัด (มหาชน)  
304 อาคารวานิชเพลซ อารีเอ (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 [www.xbio.co.th](http://www.xbio.co.th)

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 [www.xbio.co.th](http://www.xbio.co.th)

- (c) carrying out any other actions, which are necessary, relevant, and/or connecting with the capital increase and allotment of new ordinary shares of the Company as required by applicable laws and/or relevant regulations

However, in the event of an adjustment of XBIO-W6 or XBIO-W7 or XBIO-W8, the Company may calculate the definite exercise price and ratio, and the number of new ordinary shares to reserve for the adjustment of XBIO-W6 or XBIO-W7 or XBIO-W8 based on the market price per share of the ordinary shares of the Company, which is determined to be equivalent to the total trading value of the Company's ordinary shares divided by the total number of the Company's ordinary shares traded on the SET during 14 consecutive business days prior to the first day that the subscribers are not entitled to subscribe for the new ordinary shares (the first day that SET posts the XR sign). The Company shall later inform the exact adjustment of such warrants via the SET system.

The Company would therefore like to notify the shareholders' entitlement to subscribe for the new ordinary shares of the Company according to the number indicated in the Certificate of Rights to Subscribe for New Ordinary Shares Issued by Thailand Securities Depository Co., Ltd. (**Enclosure 1**). The details of the share subscription are set out in the attached Notice of the Allotment and Subscription Documents of New Ordinary Shares of X Bioscience Public Company Limited (**Enclosure 2**).

If shareholders intend to subscribe for the newly issued ordinary share, please fill in the details and sign the Subscription Form for Newly Issued Ordinary Shares enclosed herewith this letter (**Enclosure 3**). Please follow the subscription procedures specified in the Notification of Allocation of Newly Issued Ordinary Shares of the Company. In the case that shareholders subscribing to these newly issued ordinary shares who wish for the Company to deliver the securities by depositing the shares into the Issuer Account No. 600, shareholders are requested to fill in additional details and sign the accompanying documents sent together herewith (**Enclosure 5**) and complete the FATCA/CRS Self-Certification Form for Entity/Juristic Person (**Enclosure 7**) for submission to the Thailand Securities Depository.

The Company will open the subscription period for newly issued ordinary shares from 23 February to 6 March 2026 (a total of 9 business days), from 9:00 a.m. to 4:00 p.m. Existing shareholders may submit subscription documents for newly issued ordinary shares at X Bioscience Public Company Limited, No. 304, Vanit Place Aree Tower (Tower A), 18th Floor, Room No.1803-1806, Phaholyothin Road, Samsen Nai Subdistrict, Phaya Thai District, Bangkok 10400. Please refer to the map of the subscription document submission location (**Enclosure 6**). For further information, please contact Tel. 02-278-5455 or email: [investor@xbio.co.th](mailto:investor@xbio.co.th)



บริษัท เอ็กซ์ไบโอไซเอนซ์ จำกัด (มหาชน)  
304 อาคารวานิชเพลส อารีย์ (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 www.xbio.co.th

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 www.xbio.co.th

## Subscription Procedures and Payment for Newly Issued Ordinary Shares

Shareholders may subscribe for the newly issued ordinary shares at the Company during business days from 23 February to 6 March 2026, between 9.00 a.m. and 4.00 p.m. (total of 9 business days). Shareholders wishing to subscribe must accurately and completely fill in and sign the subscription form for newly issued ordinary shares. The subscriber must complete payment in full and submit the subscription form together with proof of payment and supporting documents at the designated subscription location within the subscription period. Payment may be made by one of the following methods:

### 1. Payment by cheque, cashier's cheque, or draft

The cheque, cashier's cheque, or draft must be crossed and made payable to "X Bioscience Public Company Limited", during the period from 23 February to 4 March 2026, between 9.00 a.m. and 4.00 p.m. The instrument must be collectible through a clearing house in Bangkok within one business day and dated the same day as the subscription date, but not later than 4 March 2026. The subscriber's name and contact telephone number must be written on the back of the cheque, cashier's cheque, or draft. One payment instrument is required per one subscription form.

### 2. Payment by bank transfer

Payment may be transferred to the Company's bank account as follows, "Account Name: X Bioscience Public Company Limited, Kasikornbank Public Company Limited, Phaholyothin Office Branch, Current Account, Account No. 223-8-87725-6"

Shareholders may subscribe and transfer payment between 9.00 a.m. and 4.00 p.m., from 23 February to 6 March 2026. Subscribers must attach deposit/transfer evidence and provide complete information, including the subscriber's full name, contact telephone number, 10-digit shareholder registration number (as shown in the subscription rights certificate), and 13-digit identification number, together with the required supporting documents. Each transfer must be made once per subscription form. Any bank fees (if any) shall be borne by the subscriber separately from the subscription amount.




บริษัท เอ็กซ์ไบโอไซเอนซ์ จำกัด (มหาชน)  
304 อาคารวานิชเพลส อารีย์ (อาคารA) ชั้นที่ 18 ห้อง  
เลขที่ 1803-1806 ถนนพหลโยธิน แขวงสามเสนใน  
เขตพญาไท กรุงเทพมหานคร 10400  
โทรศัพท์ 02 278 5456 [www.xbio.co.th](http://www.xbio.co.th)

X BIOSCIENCE PUBLIC COMPANY LIMITED  
304 VANIT PLACE AREE TOWER (TOWER A), ROOM  
NO.1803-1806, 18 FLOOR, PHAHON YOTHIN ROAD,  
SAMSEN NAI, PHAYA THAI, BANGKOK 10400  
Tel. 02 278 5456 [www.xbio.co.th](http://www.xbio.co.th)

X Bioscience Public Company Limited has published the subscription documents for the newly issued ordinary shares of the Company, together with the relevant supporting documents, on the Company's website at [www.xbio.co.th](http://www.xbio.co.th) under the "Investor Relations" section, in the "Publication Documents" category, from 13 February 2026 onwards. This is to enable shareholders to download and review the information prior to subscribing for the Company's newly issued ordinary shares.

In this regard, shareholders may also download the subscription documents and related supporting materials via the QR Code provided below.



Please be informed accordingly.

Yours respectfully,

X Bioscience Public Company Limited

( Ms. Saowanee Khaoubol )

Acting Chief Executive Officer and

Vice Chairman of the Board of Directors